BRD4: An emerging prospective therapeutic target in glioma: Molecular Therapy - Oncolytics
BET inhibitors in the treatment of hematologic malignancies: current i | OTT
BeT inhibitors in ongoing early-phase clinical trials for hematologic... | Download Table
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors | Journal of Clinical Oncology
Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction | Nature Communications
Achieving clinical success with BET inhibitors as anti-cancer agents | British Journal of Cancer
BET inhibitors in the treatment of hematologic malignancies: current i | OTT
Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma | EMBO Molecular Medicine
Drug Toxicities With BET Inhibitors in Clinical Trials a | Download Table
Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer: Trends in Pharmacological Sciences
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma - Annals of Oncology
Cancers | Free Full-Text | Role of BET Inhibitors in Triple Negative Breast Cancers | HTML
Bromodomain protein inhibition: a novel therapeutic strategy in rheumatic diseases | RMD Open
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency - ScienceDirect
Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence | Semantic Scholar
Ongoing clinical trials evaluating BET inhibitors in hematological cancers. | Download Scientific Diagram
Frontiers | Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases | Pharmacology
Drug Toxicities With BET Inhibitors in Clinical Trials a | Download Table
Clinical trials of bromodomain and extra-terminal inhibitors. | Download Table
Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer - ScienceDirect
Bromodomain Inhibitor Design For Epigenetic Cancer Therapies and Chemical Probes | Pomerantz Laboratory
Novel BRD4/JAK2 Dual Inhibitor Cancer Therapeutics | Moffitt
Targeting Brd4 for cancer therapy: inhibitors and degraders - MedChemComm (RSC Publishing)
Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4 | Oncogenesis
Novel brd4 inhibitors with a unique scaffold exhibit antitumor effects
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression - ScienceDirect
Targeting Brd4 for cancer therapy: inhibitors and degraders - MedChemComm (RSC Publishing) DOI:10.1039/C8MD00198G
